Patents by Inventor Lee W. Riley
Lee W. Riley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8124110Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: August 23, 2011Date of Patent: February 28, 2012Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz - FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Publication number: 20110311570Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: August 23, 2011Publication date: December 22, 2011Inventors: Albert I. Ko, Mitermayer Galvao Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 8021673Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: April 1, 2011Date of Patent: September 20, 2011Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvào Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Publication number: 20110182924Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Inventors: ALBERT I KO, MITERMAYER GALVÃO REIS, JULIO HENRIQUE ROSA CRODA, ISADORA CRISTINA SIQUEIRA, DAVID A. HAAKE, JAMES MATSUNAGA, LEE W. RILEY, MICHELE BAROCCHI, TRACY ANN YOUNG
-
Patent number: 7935357Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: March 19, 2010Date of Patent: May 3, 2011Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Publication number: 20100183656Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: March 19, 2010Publication date: July 22, 2010Inventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 7718183Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: GrantFiled: January 17, 2006Date of Patent: May 18, 2010Assignees: The United States of America represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz—FIOCRUZInventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
-
Patent number: 6995255Abstract: One aspect of the present invention relates to a nucleic acid construct which includes a first nucleic acid and a second nucleic acid operatively coupled to the first nucleic acid. The first nucleic acid molecule encodes a first peptide that has the sequence of InvX or another sequence incorporating the 58 amino acid cellular import region of Mce1A and confers on Mycobacterium tuberculosis an ability to enter mammalian cells. The second nucleic acid molecule encoding a second peptide. Expression of the nucleic acid construct produces a fusion protein comprising the first peptide coupled to the second peptide. The second peptide may be a therapeutic or a diagnostic peptide. An alternative embodiment of the nucleic acid construct includes the first nucleic acid and an insertion site suitable for incorporation of the second nucleic acid molecule into this version of the construct.Type: GrantFiled: March 4, 2003Date of Patent: February 7, 2006Assignee: The Regents of the University of CaliforniaInventors: Lee W. Riley, Sangwei Lu
-
Publication number: 20040058323Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.Type: ApplicationFiled: September 19, 2002Publication date: March 25, 2004Inventors: Albert I. Ko, Mitermayer Galvao Reis, Julio Henrique Croda, Isadora Cristina Siqueira, James Matsunaga, Lee W. Riley, Michele A. Barocchi, Tracy Ann Young
-
Patent number: 6509151Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. The protein encoded by this gene fragment is useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: February 22, 1995Date of Patent: January 21, 2003Assignee: Cornell Research Foundation, Inc.Inventor: Lee W. Riley
-
Patent number: 6399764Abstract: The present invention relates to DNA molecules associated with conferring on Mycobacterium tuberculosis an ability to enter mammalian cells. The protein encoded by these DNA molecules are useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: May 18, 2000Date of Patent: June 4, 2002Assignee: Cornell Research Foundation, IncInventor: Lee W. Riley
-
Publication number: 20010019716Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. Peptides, proteins, or polypeptides (e.g. the Mycobacterium cell entry protein or Mcep) encoded by this gene fragment are useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against these peptides, proteins, or polypeptides can be employed in passively immunizing those already infected by the organism. These proteins, peptides, polypeptides, and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The peptides, proteins, or polypeptides of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: ApplicationFiled: January 4, 2001Publication date: September 6, 2001Inventors: Lee W. Riley, Pele Chong
-
Patent number: 6224881Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. Peptides, proteins, or polypeptides (e.g. the Mycobacterium cell entry protein or Mcep) encoded by this gene fragment are useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against these peptides, proteins, or polypeptides can be employed in passively immunizing those already infected by the organism. These proteins, peptides, polypeptides, and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The peptides, proteins, or polypeptides of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: August 7, 1996Date of Patent: May 1, 2001Assignees: Cornell Research Foundation, Inc., Connaught Laboratories LimitedInventors: Lee W. Riley, Pele Chong
-
Patent number: 6214543Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. The protein encoded by this gene fragment is useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: June 5, 1995Date of Patent: April 10, 2001Assignee: Cornell Research Foundation, Inc.Inventor: Lee W. Riley
-
Patent number: 6177086Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis resistance to antimicrobial reactive oxygen intermediates and reactive nitrogen intermediates. The protein encoded by this DNA molecule is useful in vaccines to prevent invention by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein or polypeptide is also useful as a therapeutic in treating conditions mediated by the production of reactive oxygen intermediates and nitrogen intermediates.Type: GrantFiled: April 28, 1998Date of Patent: January 23, 2001Assignee: Cornell Research Foundation, Inc.Inventors: Lee W. Riley, Carl F. Nathan, Sabine Ehrt
-
Patent number: 6072048Abstract: The present invention relates to DNA molecules associated with conferring on Mycobacterium tuberculosis an ability to enter mammalian cells. The protein encoded by these DNA molecules are useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: August 6, 1997Date of Patent: June 6, 2000Assignee: Cornell Research Foundation, Inc.Inventor: Lee W. Riley
-
Patent number: 6008201Abstract: The present invention relates to a DNA molecule conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages. The protein encoded by this gene fragment is useful in vaccines to prevent infection by Mycobacterium tuberculosis, while the antibodies raised against this protein can be employed in passively immunizing those already infected by the organism. Both these proteins and antibodies may be utilized in diagnostic assays to detect Mycobacterium tuberculosis in tissue or bodily fluids. The protein of the present invention can be associated with various other therapeutic materials, for administration to mammals, particularly humans, to achieve uptake of those materials by such cells.Type: GrantFiled: June 5, 1995Date of Patent: December 28, 1999Assignee: Cornell Research Foundation, Inc.Inventor: Lee W. Riley